@FierceBiotech: We have another new Fierce addition! Please say hello to @MarkHfierce, who will be covering drug delivery, biotech research and more. News | Follow @FierceBiotech
@JohnCFierce: So Verastem has now raised $68M in VC cash; spent $8.5M and wants a $50M IPO. Sure. Article | Follow @JohnCFierce
@RyanMFierce: After what's happened at $DNDN, folks will look very carefully at next crop of cancer vax developers like NewLink. | Follow @RyanMFierce
@MaureenFierce: Reading: Resveratrol in humans: Results of a controlled trial. Blog entry | Follow @MaureenFierce
> The FDA has opted to not approve Alimera's ($ALIM) application for its eye drug Iluvien for treating diabetic macular edema. News of the agency's Complete Response Letter prompted a selloff of Alimera stock and that of pSivida ($PSDV), which provides the drug delivery tech for the experimental eye drug. Alimera release
> Napo Pharmaceuticals said that it has nixed its collaboration agreement with Salix Pharmaceuticals related to Napo's developmental diarrhea candidate crofelemer. Item
> Venture capitalist Bruce Booth gives his take on the facts and fictions associated with "virtual biotechs," which has been favored as a limber model for advancing drugs. Blog post
> New York Blood Center has garnered the first FDA approval for its hematopoietic progenitor cells-cord cell therapy used in the treatment of cancer patients. Update
> Affymax has received $13 million in its settlement with Janssen Biotech related to a patent on peginesatide. Report
> Florida's Vaccine and Gene Therapy Institute (VGTI) has spun off a new upstart called TomegaVax to advance vaccines technology that could be useful in providing new attacks against HIV, tuberculosis and hepatitis C. Interview
Pharma News
@FiercePharma: Are the best times for Big Pharma in China already over? Or will volume make up for new price cuts? Bloomberg: Article | Follow @FiercePharma
> Analysts handicap Ranbaxy's Lipitor copycat. Report
> Less cash, more promises in pay-to-delay deals. Story
> Teva: 'Too early' to say whether merger triggers job cuts. Report
> IntelGenx antidepressant gets FDA nod, but no launch yet. Item
> Aggressive pricing tarnishes China's promise to pharma. News
> Doxil shortage drags on, with J&J exec citing 'limited options.' Story
And Finally... We salute our nation's military veterans today. Thank you for your sacrifices.